At a glance Drug / evolocumab (Repatha), a PCSK9-inhibitor biologic antibody Supplement / glutathione (oral, liposomal, or IV forms) Known interaction / none documented in published literature or FDA label Interaction type / not applicable, no shared metabolic pathway identified Evolocumab clearance / proteolytic catabolism, not CYP450 or GSH-dependent Glutathione CYP effect / negligible at typical oral doses (250 to 1,000 mg/day) LDL-C reduction with evolocumab / up to 59% vs
It also comprises key residues that facilitate the GSH-based nucleophilic attack on the electrophilic substrate, leading to the formation of a thioether bond and the subsequent detoxification of the substrate
Anal Biochem 98(1):154159 Massa CM, Liu Z, Taylor S, Pettit AP, Stakheyeva MN, Korotkova E, Popova V, Atochina-Vasserman EN, Gow AJ (2021) Biological mechanisms of S-nitrosothiol formation and degradation: how is specificity of S-nitrosylation achieved
Appreciate that
TUNEL Assay To assess tubular cell death, TUNEL assay was used on kidney section embedded in paraffin according to the products protocols (Roche, Basel, Switzerland)
